Welcome to the UPF Digital Repository

An open-label, multicenter, randomized, phase II study of Cisplatin and Pemetrexed with or without Cixutumumab (IMC-A12) as a first-line therapy in patients with advanced nonsquamous non-small cell lung cancer.



An open-label, multicenter, randomized, phase II study of Cisplatin and Pemetrexed with or without Cixutumumab (IMC-A12) as a first-line therapy in patients with advanced nonsquamous non-small cell lung cancer.

Thumbnail
Document Type: Article
Version: Published version
Date: 2017
This document is associated with a Creative Common license ª 2016 International Association for the Study of Lung Cancer. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

This item appears in the following Collection(s)

Search DSpace


Advanced Search

Browse

My Account

Statistics

Compliant to Partaking